drugset / Trial / NCT01311739
Oral Cyanocobalamin (Eligen B12) Bioavailability Study
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess and compare the pharmacokinetics (PK) of cyanocobalamin after the oral administration of Eligen® B12 (cyanocobalamin/SNAC), oral cyanocobalamin alone (commercially-available formulation) and cyanocobalamin administered intravenously (IV) (also a commercially-available formulation) to healthy male subjects under fasting conditions. The safety and tolerability of oral Eligen® B12 (cyanocobalamin/SNAC) versus oral cyanocobalamin alone and versus IV cyanocobalamin are also assessed.
Timeline
- Start
- 2008-05
- Primary completion
- —
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vitamin B12 | Other / unclassified | 1 mg | Oral |
| Subject | Vitamin B12 | Other / unclassified | 5 mg | Oral |
| Subject | Vitamin B12 | Other / unclassified | 10 mg | Oral |
Indications
No indication recorded.